0000950123-23-005321.txt : 20230515 0000950123-23-005321.hdr.sgml : 20230515 20230515161244 ACCESSION NUMBER: 0000950123-23-005321 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 EFFECTIVENESS DATE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 23922389 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml X0202 13F-HR LIVE 0001703031 XXXXXXXX 03-31-2023 03-31-2023 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of Annexon, Inc. ("ANNX") are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP and BCLS I Investco, LP on 2/14/23 and reflect the exercise of securities held by such persons for ANNX common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the ANNX common stock following such exercise. As of 3/31/23, such persons held 3,601,926 shares of ANNX common stock. The shares of Disc Medicine, Inc. ("IRON") are as reported on the Schedule 13G filed by Bain Capital Life Sciences Opportunities III, LP on 2/24/23 and reflect the exercise of securities held by such person for IRON common stock, after giving effect to provisions that prevent exercise if such person would beneficially own more than 9.99% of the IRON common stock following such exercise. As of 3/31/23, such person held 944,687 shares of IRON common stock. The shares of Savara Inc. ("SVRA") are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on 3/17/21 and reflect the exercise of securities held by such persons for SVRA common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SVRA common stock following such exercise. As of 3/31/23, such persons held 6,913,208 shares of SVRA common stock. The shares of Syros Pharmaceuticals, Inc. ("SYRS") are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Equity Opportunities, LP on 2/14/23 and reflect the exercise of securities held by such persons for SYRS common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SYRS common stock following such exercise. As of 3/31/23, such persons held 1,082,404 shares of SYRS common stock. The shares of X4 Pharmaceuticals, Inc. ("XFOR") are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP and BCLS I Investco, LP on 2/14/23 and reflect the exercise of securities held by such persons for XFOR common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the XFOR common stock following such exercise. As of 3/31/23, such persons held 11,590,336 shares of XFOR common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 05-15-2023 11 34 800117 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 28-20816 Bain Capital Life Sciences Investors II, LLC 5 28-20814 Bain Capital Life Sciences Fund II, L.P. 6 28-22976 BCLS II Investco (GP), LLC 7 28-22978 BCLS II Investco, LP 8 28-22975 Bain Capital Life Sciences III General Partner, LLC 9 28-22979 Bain Capital Life Sciences Fund III, L.P. 10 28-22968 Bain Capital Life Sciences Opportunities III GP, LLC 11 28-22966 Bain Capital Life Sciences Opportunities III, LP INFORMATION TABLE 2 23321.xml INFORMATION TABLE FOR FORM 13F 2SEVENTY BIO INC COMMON STOCK 901384107 14371 1408901 SH SOLE 1408901 0 0 ACLARIS THERAPEUTICS INC COM 00461U105 27506 3400000 SH SOLE 3400000 0 0 AEGLEA BIOTHERAPEUTICS INC COM 00773J103 1551 5347689 SH SOLE 5347689 0 0 ANNEXON INC COM 03589W102 18813 4886616 SH SOLE 4886616 0 0 APTINYX INC COM 03836N103 1110 8891758 SH SOLE 8891758 0 0 ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 33000 3000000 SH SOLE 3000000 0 0 ATEA PHARMACEUTICALS INC COM 04683R106 8327 2485638 SH SOLE 2485638 0 0 C4 THERAPEUTICS INC COM STK 12529R107 5157 1642210 SH SOLE 1642210 0 0 CARA THERAPEUTICS INC COM 140755109 10824 2204449 SH SOLE 2204449 0 0 CRINETICS PHARMACEUTICALS IN COM 22663K107 37027 2305558 SH SOLE 2305558 0 0 CTI BIOPHARMA CORP COM 12648L601 19753 4702996 SH SOLE 4702996 0 0 CYMABAY THERAPEUTICS INC COM 23257D103 21800 2500000 SH SOLE 2500000 0 0 DISC MEDICINE INC COM 254604101 42187 1990914 SH SOLE 1990914 0 0 DYNAVAX TECHNOLOGIES CORP COM NEW 268158201 38406 3915000 SH SOLE 3915000 0 0 EQRX INC COM 26886C107 19407 10003573 SH SOLE 10003573 0 0 INVIVYD INC COM 00534A102 2325 1937207 SH SOLE 1937207 0 0 MARINUS PHARMACEUTICALS INC COM NEW 56854Q200 9874 1431058 SH SOLE 1431058 0 0 MERSANA THERAPEUTICS INC COM 59045L106 35608 8663673 SH SOLE 8663673 0 0 NATERA INC COM 632307104 38875 700197 SH SOLE 700197 0 0 NAUTILUS BIOTECHNOLOGY INC COM 63909J108 5540 2000000 SH SOLE 2000000 0 0 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES N62509109 110058 8300000 SH SOLE 8300000 0 0 NEWAMSTERDAM PHARMA COMPANY *W EXP 11/22/202 N62509117 184 100000 SH SOLE 100000 0 0 NURIX THERAPEUTICS INC COM 67080M103 16187 1822883 SH SOLE 1822883 0 0 NUVALENT INC COM 670703107 93331 3577267 SH SOLE 3577267 0 0 PHARVARIS N V COM N69605108 25620 3180601 SH SOLE 3180601 0 0 RAPID MICRO BIOSYSTEMS INC CLASS A COM 75340L104 11049 8434560 SH SOLE 8434560 0 0 SAVARA INC COM 805111101 22664 11622598 SH SOLE 11622598 0 0 SOLID BIOSCIENCES INC COM NEW 83422E204 14838 3130422 SH SOLE 3130422 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 79313 3081307 SH SOLE 3081307 0 0 SYROS PHARMACEUTICALS INC COM NEW 87184Q206 5673 2124694 SH SOLE 2124694 0 0 TANGO THERAPEUTICS INC COM 87583X109 7591 1921790 SH SOLE 1921790 0 0 THIRD HARMONIC BIO INC COM 88427A107 2639 640631 SH SOLE 640631 0 0 X4 PHARMACEUTICALS INC COM 98420X103 10616 12202510 SH SOLE 12202510 0 0 XILIO THERAPEUTICS INC COM 98422T100 8893 2805413 SH SOLE 2805413 0 0